臺灣博碩士論文加值系統

研究背景
Adiponectin是血液中含量最多的脂肪細胞激素(Adipokine)，其本身具有增加胰島素敏感性和抗發炎反應的特性。然而，在慢性腎臟病(CKD)族群的血液中，adiponectin會因為腎臟清除率降低，調節慢性腎臟病生理機制的代償反應，或者adiponectin阻抗性等等原因而上升。因此，這篇研究目的在於觀察在非糖尿病相關之腎臟病病人中，考慮到身體組成成分及代謝症候群，血中adiponectin和進展到末期腎臟病(ESRD)的關聯性。
研究方法
這篇觀察性研究從2010年到2017年，共蒐集了194位非糖尿病相關之腎臟病病人，其腎絲球過濾率(eGFR)介於10到60 ml/min/1.73 m2，利用MILLIPLEX MAP Human Serum Adipokine Panel A kit (Millipore, Billerica, MA)檢驗血中adiponectin濃度，並根據濃度將病人分組成三分位(tertile)，就其結果進行相關統計及分析。
結果
在平均五年之追蹤期間，共47位(24.2%)的病人進展到末期腎臟病。Adiponectin血中濃度中位數為29.4μg/ml (interquartile range, 13.3-108.7)。我們發現adiponectin濃度和身體質量指數(BMI) (r = -0.29; P < 0.001)及腰圍(r = -0.35; P < 0.001)呈負相關。經過分層Cox迴歸模式分析後，adiponectin進展到末期腎臟病之風險比(hazard ratio)為3.41 (95% CI, 1.56 to 7.46; P=0.002)。且次組別分析中，未發現和adiponectin有交互作用的情形。
結論
總而言之，在非糖尿病相關之慢性腎臟病的病人中，即使考慮了傳統的風險因子後，血液中較高的adiponectin仍有較高的獨立風險會進展到末期腎臟病。未來仍需要其他研究來證實因果關係，證實降低adiponectin後是否可減緩慢性腎臟病的進展。

Background
Adiponectin is the most abundant circulating adipokine which possesses insulin-sensitizing and anti-inflammatory properties. However, elevated adiponectin associated with kidney function declines are attributed to decreased clearance, compensatory response or adiponectin resistance. Therefore, the aim of this study is to examine the association between serum adiponectin and end-stage renal disease (ESRD) risk in those with non-diabetic chronic kidney disease (CKD) accounted for differences in body composition and metabolic syndrome components.
Methods
This was an observational study from 2010 to 2017. We enrolled 194 non-diabetic CKD patients with a eGFR range of between 10 and 60 ml/min/1.73 m2, who were categorized into tertiles based on serum adiponectin concentration. Adiponectin were measured using the MILLIPLEX MAP Human Serum Adipokine Panel A kit (Millipore, Billerica, MA). The primary end point was defined as renal failure requiring renal replacement therapy.

Results
During a mean follow-up of 5 years, 47(24.2%) incident cases of ESRD were observed. The mean eGFR was 30.0 ± 12.7 mL/min/1.73m2. The baseline median adiponectin concentration in the cohort was 29.4μg/ml (interquartile range, 13.3-108.7). Adiponectin levels were inversely related to BMI (r = -0.29; P < 0.001) and waist circumference (r = -0.35; P < 0.001). In fully adjusted Cox regression model, hazard ratio (HR) for ESRD was 3.41 (95% CI, 1.56 to 7.46; P = 0.002). Besides, we did not detect effect modification between different subgroups.
Conclusions
In conclusion, higher adiponectin was associated with higher risk for ESRD independent of conventional risk factors in patients with non-diabetic CKD, including metabolic syndrome or body composition.

中文摘要………………………………………………………3
英文摘要 Abstract………………………………5
誌謝……………………………………………………………7
前言 Introduction ………………………8
材料與方法 Materials and methods…………………………11
結果 Results………………………………………………….16
討論 Discussion………………………………………………19
結論 Conclusion………………………………………………26
參考文獻 References…………………………………………27
附表 Tables…………………………………………………..33
附圖 Figures…………………………………………………38

Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012;94(10):2137-42. Epub 2012/06/21. doi: 10.1016/j.biochi.2012.06.008. PubMed PMID: 22713764.
2.Ebrahimi-Mamaeghani M, Mohammadi S, Arefhosseini SR, Fallah P, Bazi Z. Adiponectin as a potential biomarker of vascular disease. Vascular health and risk management. 2015;11:55-70. Epub 2015/02/06. doi: 10.2147/vhrm.s48753. PubMed PMID: 25653535; PubMed Central PMCID: PMCPMC4303398.
3.Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, et al. New insight into adiponectin role in obesity and obesity-related diseases. BioMed research international. 2014;2014:658913. Epub 2014/08/12. doi: 10.1155/2014/658913. PubMed PMID: 25110685; PubMed Central PMCID: PMCPMC4109424.
4.Matsuda M, Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Reviews in endocrine & metabolic disorders. 2014;15(1):1-10. Epub 2013/09/13. doi: 10.1007/s11154-013-9271-7. PubMed PMID: 24026768.
5.Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007;115(11):1408-16. Epub 2007/03/07. doi: 10.1161/circulationaha.106.666941. PubMed PMID: 17339545.
6.Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet (London, England). 2003;361(9353):226-8. Epub 2003/01/28. doi: 10.1016/s0140-6736(03)12255-6. PubMed PMID: 12547549.
7.Shand BI, Scott RS, Elder PA, George PM. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes, obesity & metabolism. 2003;5(5):349-53. Epub 2003/08/28. PubMed PMID: 12940874.
8.Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K, et al. Association of low adiponectin levels with the metabolic syndrome--the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism: clinical and experimental. 2005;54(4):476-81. Epub 2005/03/31. doi: 10.1016/j.metabol.2004.10.016. PubMed PMID: 15798954.
9.Rhee CM, Nguyen DV, Moradi H, Brunelli SM, Dukkipati R, Jing J, et al. Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2015;66(2):313-21. Epub 2015/04/01. doi: 10.1053/j.ajkd.2015.02.325. PubMed PMID: 25824125; PubMed Central PMCID: PMCPMC4516594.
10.Zoccali C, Postorino M, Marino C, Pizzini P, Cutrupi S, Tripepi G. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. Journal of internal medicine. 2011;269(2):172-81. Epub 2010/12/09. doi: 10.1111/j.1365-2796.2010.02288.x. PubMed PMID: 21138492.
11.Delgado C, Chertow GM, Kaysen GA, Dalrymple LS, Kornak J, Grimes B, et al. Associations of Body Mass Index and Body Fat With Markers of Inflammation and Nutrition Among Patients Receiving Hemodialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017;70(6):817-25. Epub 2017/09/06. doi: 10.1053/j.ajkd.2017.06.028. PubMed PMID: 28870376.
12.Hyun YY, Lee KB, Oh KH, Ahn C, Park SK, Chae DW, et al. Serum adiponectin and protein-energy wasting in predialysis chronic kidney disease. Nutrition (Burbank, Los Angeles County, Calif). 2017;33:254-60. Epub 2016/10/04. doi: 10.1016/j.nut.2016.06.014. PubMed PMID: 27692989.
13.Yoon CY, Kim YL, Han SH, Yoo TH, Sung SA, Chung WK, et al. Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study. Diabetology & metabolic syndrome. 2016;8:75. Epub 2016/11/30. doi: 10.1186/s13098-016-0191-z. PubMed PMID: 27895721; PubMed Central PMCID: PMCPMC5109641.
14.Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2004;43(6):1047-55. Epub 2004/05/29. PubMed PMID: 15168385.
15.Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. Journal of the American Society of Nephrology : JASN. 2005;16(4):1091-8. Epub 2005/03/04. doi: 10.1681/asn.2004090742. PubMed PMID: 15743998.
16.Nanayakkara PW, Le Poole CY, Fouque D, van Guldener C, Stehouwer CD, Smulders YM, et al. Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3 - 5 chronic kidney disease. Clinical nephrology. 2009;72(1):21-30. Epub 2009/07/31. PubMed PMID: 19640384.
17.Mills KT, Hamm LL, Alper AB, Miller C, Hudaihed A, Balamuthusamy S, et al. Circulating adipocytokines and chronic kidney disease. PloS one. 2013;8(10):e76902. Epub 2013/10/12. doi: 10.1371/journal.pone.0076902. PubMed PMID: 24116180; PubMed Central PMCID: PMCPMC3792047.
18.Ortega Moreno L, Lamacchia O, Copetti M, Salvemini L, De Bonis C, De Cosmo S, et al. Serum Adiponectin and Glomerular Filtration Rate in Patients with Type 2 Diabetes. PloS one. 2015;10(10):e0140631. Epub 2015/10/16. doi: 10.1371/journal.pone.0140631. PubMed PMID: 26465607; PubMed Central PMCID: PMCPMC4605700.
19.Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney international Supplement. 2003;(84):S98-102. Epub 2003/04/16. doi: 10.1046/j.1523-1755.63.s84.49.x. PubMed PMID: 12694320.
20.Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2005;20(1):129-34. Epub 2004/12/09. doi: 10.1093/ndt/gfh568. PubMed PMID: 15585515.
21.Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney international. 2007;71(12):1279-86. Epub 2007/04/26. doi: 10.1038/sj.ki.5002191. PubMed PMID: 17457380.
22.Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney international. 2008;74(5):649-54. Epub 2008/05/23. doi: 10.1038/ki.2008.201. PubMed PMID: 18496510.
23.Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. Jama. 2004;291(14):1730-7. Epub 2004/04/15. doi: 10.1001/jama.291.14.1730. PubMed PMID: 15082700.
24.Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. Journal of the American Society of Nephrology : JASN. 2006;17(9):2599-606. Epub 2006/08/04. doi: 10.1681/asn.2006040331. PubMed PMID: 16885405.
25.Sakura T, Okuno S, Nishio E, Norimine K, Ishimura E, Yamakawa T, et al. The association of serum adiponectin with abdominal aortic calcification in Japanese male hemodialysis patients: a cross-sectional observational study. Scientific reports. 2017;7(1):6434. Epub 2017/07/27. doi: 10.1038/s41598-017-06850-4. PubMed PMID: 28743977; PubMed Central PMCID: PMCPMC5526980.
26.Tsigalou C, Chalikias G, Kantartzi K, Tziakas D, Kampouromiti G, Vargemezis V, et al. Differential effect of baseline adiponectin on all-cause mortality in hemodialysis patients depending on initial body mass index. Long-term follow-up data of 4.5 years. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2013;23(1):45-56. Epub 2012/03/13. doi: 10.1053/j.jrn.2011.12.007. PubMed PMID: 22406123.
27.Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2006;48(5):727-38. Epub 2006/10/25. doi: 10.1053/j.ajkd.2006.07.018. PubMed PMID: 17059992.
28.Hwang SJ, Yang WC, Lin MY, Mau LW, Chen HC. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2010;25(8):2616-24. Epub 2010/06/04. doi: 10.1093/ndt/gfq308. PubMed PMID: 20519231.
29.Liu J, Grundy SM, Wang W, Smith SC, Jr., Vega GL, Wu Z, et al. Ethnic-specific criteria for the metabolic syndrome: evidence from China. Diabetes care. 2006;29(6):1414-6. Epub 2006/05/30. doi: 10.2337/dc06-0481. PubMed PMID: 16732037.
30.Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. Journal of the American Society of Nephrology : JASN. 2002;13(1):134-41. Epub 2001/12/26. PubMed PMID: 11752030.
31.Wang J, Li H, Franco OH, Yu Z, Liu Y, Lin X. Adiponectin and metabolic syndrome in middle-aged and elderly Chinese. Obesity (Silver Spring, Md). 2008;16(1):172-8. Epub 2008/01/29. doi: 10.1038/oby.2007.42. PubMed PMID: 18223631.
32.Zha D, Wu X, Gao P. Adiponectin and Its Receptors in Diabetic Kidney Disease: Molecular Mechanisms and Clinical Potential. Endocrinology. 2017;158(7):2022-34. Epub 2017/04/13. doi: 10.1210/en.2016-1765. PubMed PMID: 28402446.
33.Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103(8):1057-63. Epub 2001/02/27. PubMed PMID: 11222466.
34.Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102(11):1296-301. Epub 2000/09/12. PubMed PMID: 10982546.
35.Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-6. Epub 1999/12/22. PubMed PMID: 10604883.
36.Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and biophysical research communications. 2004;323(2):630-5. Epub 2004/09/17. doi: 10.1016/j.bbrc.2004.08.145. PubMed PMID: 15369797.
37.Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459-69. Epub 2003/04/11. doi: 10.1007/s00125-003-1074-z. PubMed PMID: 12687327.
38.Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. The Journal of clinical investigation. 2006;116(7):1784-92. Epub 2006/07/11. doi: 10.1172/jci29126. PubMed PMID: 16823476; PubMed Central PMCID: PMCPMC1483172.
39.Sanches FM, Avesani CM, Kamimura MA, Lemos MM, Axelsson J, Vasselai P, et al. Waist circumference and visceral fat in CKD: a cross-sectional study. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2008;52(1):66-73. Epub 2008/04/29. doi: 10.1053/j.ajkd.2008.02.004. PubMed PMID: 18440683.
40.Yaturu S, Reddy RD, Rains J, Jain SK. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine. 2007;37(1):1-5. Epub 2007/03/27. doi: 10.1016/j.cyto.2007.02.003. PubMed PMID: 17383891.
41.Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2007;22(1):171-8. Epub 2006/09/29. doi: 10.1093/ndt/gfl552. PubMed PMID: 17005524.
42.Komaba H, Igaki N, Goto S, Yokota K, Doi H, Takemoto T, et al. Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients with impaired renal function. American journal of nephrology. 2006;26(5):476-82. Epub 2006/11/11. doi: 10.1159/000096870. PubMed PMID: 17095862.
43.Martinez Cantarin MP, Waldman SA, Doria C, Frank AM, Maley WR, Ramirez CB, et al. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney international. 2013;83(3):487-94. Epub 2013/01/04. doi: 10.1038/ki.2012.421. PubMed PMID: 23283133; PubMed Central PMCID: PMCPMC3587362.
44.Martinez Cantarin MP, Keith SW, Waldman SA, Falkner B. Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2014;29(12):2268-77. Epub 2014/07/23. doi: 10.1093/ndt/gfu249. PubMed PMID: 25049200; PubMed Central PMCID: PMCPMC4240178.
45.Nerpin E, Riserus U, Ingelsson E, Sundstrom J, Jobs M, Larsson A, et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes care. 2008;31(8):1550-5. Epub 2008/05/30. doi: 10.2337/dc08-0369. PubMed PMID: 18509205; PubMed Central PMCID: PMCPMC2494665.
46.Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. The Journal of clinical investigation. 2008;118(5):1645-56. Epub 2008/04/24. doi: 10.1172/jci32691. PubMed PMID: 18431508; PubMed Central PMCID: PMCPMC2323186.
47.Fang F, Liu GC, Kim C, Yassa R, Zhou J, Scholey JW. Adiponectin attenuates angiotensin II-induced oxidative stress in renal tubular cells through AMPK and cAMP-Epac signal transduction pathways. American journal of physiology Renal physiology. 2013;304(11):F1366-74. Epub 2013/03/29. doi: 10.1152/ajprenal.00137.2012. PubMed PMID: 23535586.
48.Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney international. 2009;76(5):567-75. Epub 2009/06/12. doi: 10.1038/ki.2009.200. PubMed PMID: 19516245.
49.Saraheimo M, Forsblom C, Thorn L, Waden J, Rosengard-Barlund M, Heikkila O, et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes care. 2008;31(6):1165-9. Epub 2008/03/19. doi: 10.2337/dc07-2306. PubMed PMID: 18346990.